Statins Drain a Battery Cancer Cells Need — and Expose a Weakness, Study Finds
Statins drain the NAD+ battery cancer cells use to make serine; in neuroblastoma models, adding a serine-blocking drug to simvastatin increased anti-tumor activity in mice.
By Sanare Lab · September 29, 2026 · 2 min read
Key Takeaway
Statins — common cholesterol-lowering drugs — do more than block cholesterol: in cancer cells they drain NAD+ (the cell's rechargeable energy carrier), which cuts production of serine, an amino acid tumors need to grow. In mice with neuroblastoma (a childhood nerve-cell cancer), pairing simvastatin with a serine-blocking drug increased anti-tumor activity. This is preclinical (animal-stage) research.
The mevalonate pathway — the chain of reactions statins block to lower cholesterol — turned out to have a second job: it keeps NAD+ regenerated through ubiquinone (coenzyme Q, part of the cell's energy machinery). When statins blocked it, the cells' oxidative phosphorylation (their main power generator) faltered, the NAD+/NADH ratio fell, and production of serine and aspartate — amino acids tumors use to build the letters of DNA — dropped.
That weakness can be exploited. Tumors make serine from scratch using an enzyme called PHGDH, and experimental drugs that block PHGDH work best when serine is already scarce. In this study, neuroblastoma cells starved by simvastatin became markedly more sensitive to the PHGDH blocker NCT-503, and the combination showed elevated anti-tumor activity in xenografts (human tumors grown in mice) compared with either approach alone.
Context: no patients were treated — the work was done in cells and mice, and any combination would need human trials. For related reading, see other repurposed-drug research in neuroblastoma and the Care Oncology Protocol, which includes a statin; for dosing questions, our dosing calculator.
In plain words
What happened: Researchers studied statins in cancer cells and tested simvastatin with a serine-blocking drug in mice with neuroblastoma.
Why it matters: Statins lowered a cell energy supply that helps make serine, a building block cells need. The team tested whether blocking serine production added to this effect.
How strong is the evidence: This was preclinical research, including a mouse model where the combination increased antitumor activity. It does not show the approach benefits children or adults with cancer.
What it means for you: Nothing changes in treatment today. Do not start or change a statin for cancer; discuss medicines with your oncologist and prescribing clinician.
References
- Nguyen TT, Ding J, Bansal M, et al. Impaired Mevalonate-Dependent NAD⁺ Regeneration Suppresses Serine Biosynthesis and Enhances Sensitivity to PHGDH Inhibition. Cancer Res. 2026 Sep 28. doi:10.1158/0008-5472.CAN-26-1063. PMID: 42804747.
Medical Disclaimer
This article is for informational purposes only and is not medical advice. The study was done in cell cultures and mice, not humans, and is not a clinical trial. Never start, stop or change any medication without consulting a licensed healthcare provider.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.